Drug Profile
KAG 308
Alternative Names: KAG-308Latest Information Update: 27 Dec 2019
Price :
$50
*
At a glance
- Originator Kaken Pharmaceutical
- Developer Asahi Glass; Kaken Pharmaceutical
- Class Anti-inflammatories
- Mechanism of Action Prostaglandin E EP4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ulcerative colitis
Most Recent Events
- 27 Dec 2019 No development reported - Phase-II for Ulcerative colitis in Japan (PO) (Kaken Pharmaceutical website, December 2019)
- 14 Apr 2016 Phase-II clinical trials in Ulcerative colitis in Japan (PO)
- 22 May 2014 Kaken Pharmaceutical completes a phase I trial in Healthy volunteers in Japan (UMIN000014009)